Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study

EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update

(2021) Annalisa Berzigotti et al.   JOURNAL OF HEPATOLOGY

Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of Nonalcoholic Fatty Liver Disease

(2020) James M. Paik et al.   HEPATOLOGY

Prevalence, predictors and severity of lean non-alcoholic fatty liver disease in HIV-infected patients

(2020) Adriana Cervo et al.   CLINICAL INFECTIOUS DISEASES

Prevalence and Risk Factors of Moderate to Severe Hepatic Steatosis in HIV Infection: The Copenhagen Co-Morbidity Liver Study

(2020) Ditte Marie Kirkegaard-Klitbo et al.   JOURNAL OF INFECTIOUS DISEASES

Expert Panel Review on Non-Alcoholic Fatty Liver Disease in Persons with HIV

(2020) Jordan E. Lake et al.   Clinical Gastroenterology and Hepatology

Optimal Threshold of Controlled Attenuation Parameter for Detection of HIV-Associated NAFLD With Magnetic Resonance Imaging as the Reference Standard

(2020) Veeral H Ajmera et al.   CLINICAL INFECTIOUS DISEASES

Diagnostic accuracy of noninvasive markers of steatosis, NASH and liver fibrosis in HIV-monoinfected individuals at-risk of non-alcoholic fatty liver disease (NAFLD)

(2018) Maud Lemoine et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Hepatic steatosis progresses faster in HIV mono-infected than HIV/HCV co-infected patients and is associated with liver fibrosis

(2017) Thomas Pembroke et al.   JOURNAL OF HEPATOLOGY

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

(2017) Zobair Younossi et al.   Nature Reviews Gastroenterology & Hepatology

Nonalcoholic fatty liver disease diagnosed by transient elastography with controlled attenuation parameter in unselected HIV monoinfected patients

(2016) Élise Vuille-Lessard et al.   AIDS

Prevalence and predictors of liver steatosis and fibrosis in unselected patients with HIV mono-infection

(2016) Rosa Lombardi et al.   DIGESTIVE AND LIVER DISEASE

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

(2016)   JOURNAL OF HEPATOLOGY

Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies

(2015) Siddharth Singh et al.   Clinical Gastroenterology and Hepatology

Risk Factors for Fatty Liver in the Multicenter AIDS Cohort Study

(2014) Jennifer C Price et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Nonalcoholic Fatty Liver Disease: MR Imaging of Liver Proton Density Fat Fraction to Assess Hepatic Steatosis

(2013) An Tang et al.   RADIOLOGY

Determination of reliability criteria for liver stiffness evaluation by transient elastography

(2012) Jérôme Boursier et al.   HEPATOLOGY

The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease

(2010) Yaron Rotman et al.   HEPATOLOGY

Harmonizing the Metabolic Syndrome

(2009) K.G.M.M. Alberti et al.   CIRCULATION

Nonalcoholic Fatty Liver Disease in HIV‐Infected Patients Referred to a Metabolic Clinic: Prevalence, Characteristics, and Predictors

(2008) Giovanni Guaraldi et al.   CLINICAL INFECTIOUS DISEASES

Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial

(2008) C. Duvivier et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY